---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-24-001179"
form_type: "8-K"
ticker: "LCTC"
cik: "0001493137"
company_name: "Lifeloc Technologies, Inc"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:49:48.251285+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lifeloc Q2 2024 net loss of $298K; rev $2.387M (+5% YoY); SpinDx beta in 2024

## Summary
- Net loss $(298K) ($0.12/diluted) vs net income $55K ($0.02) in Q2 2023.
- Revenue increased 5% to $2.387M; gross margin fell to 41.6% from 45.7%.
- R&D spending rose 67% to $662K, primarily for SpinDx saliva THC detection.
- Cash at $505K; post-quarter closed $750K credit line + $798K private placement.
- SpinDx beta testing planned H2 2024; commercial launch targeted for 2025.

## SEC filing metadata
- accession: 0001079973-24-001179
- form_type: 8-K
- ticker: LCTC
- cik: 0001493137
- company_name: Lifeloc Technologies, Inc
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1493137/000107997324001179/0001079973-24-001179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1493137/000107997324001179/lctc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-24-001179
- JSON: https://secwatch.observer/filing/0001079973-24-001179.json
- Plain text: https://secwatch.observer/filing/0001079973-24-001179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.